cdk9 cyct1 (Carna Inc)
Carna Inc is a verified supplier 
Carna Inc manufactures this product 
94
Structured Review
Carna Inc
cdk9 cyct1
Cdk9 Cyct1, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/04-110/CDK9-CycT1/pm30067358-631-12-17
Average 94 stars, based on 12 article reviews
Cdk9 Cyct1, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/04-110/CDK9-CycT1/pm30067358-631-12-17
Average 94 stars, based on 12 article reviews
cdk9 cyct1 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
In Vitro:Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: Despite the potential of cyclin-dependent kinase 9 (CDK9) as a novel target for various malignancies and HIV replication in infected cells, no effective inhibitors have been developed.. In the preceding study, we deciphered a hidden cavity in CDK9 upon molecular dynamics (MD) simulation of the CDK9/CyclinT1/Tat trimolecular complex.. This cavity is located near the CDK9 ATP pocket (continuous cavity I, CCI) and extends to the cyclin T1 (CycT1) contact surface (CCII and CCIII). Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: .. In vitro kinase assays were performed using the Recombinant:Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: Despite the potential of cyclin-dependent kinase 9 (CDK9) as a novel target for various malignancies and HIV replication in infected cells, no effective inhibitors have been developed.. In the preceding study, we deciphered a hidden cavity in CDK9 upon molecular dynamics (MD) simulation of the CDK9/CyclinT1/Tat trimolecular complex.. This cavity is located near the CDK9 ATP pocket (continuous cavity I, CCI) and extends to the cyclin T1 (CycT1) contact surface (CCII and CCIII). Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: .. In vitro kinase assays were performed using the Concentration Assay:Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: Despite the potential of cyclin-dependent kinase 9 (CDK9) as a novel target for various malignancies and HIV replication in infected cells, no effective inhibitors have been developed.. In the preceding study, we deciphered a hidden cavity in CDK9 upon molecular dynamics (MD) simulation of the CDK9/CyclinT1/Tat trimolecular complex.. This cavity is located near the CDK9 ATP pocket (continuous cavity I, CCI) and extends to the cyclin T1 (CycT1) contact surface (CCII and CCIII). Article Title: Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico Article Snippet: .. In vitro kinase assays were performed using the Kinase Assay:Article Title: Supporting Information Balancing properties with carboxylates: a lead optimization campaign for selective and orally active CDK9 inhibitors Article Snippet: Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. .. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100 were added for final reaction mixture concentrations of 1000 μM ATP, 100nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM Article Title: Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects. Article Snippet: Cyclin-dependent kinase 9 (CDK9) plays a pivotal role in regulating transcriptional elongation and has emerged as a promising target in cancer therapy.. However, it is reported that CDK9 inhibitors cause abnormal upregulation of H3K27me3 in Diffuse Large B-cell Lymphoma (DLBCL) cell lines.. Here, we designed a series of dual inhibitors targeting CDK9 and EZH2 by linking two distinct pharmacophores to achieve synergistic antitumor effects. other:Article Title: A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors Article Snippet: Article Title: A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors. Article Snippet: Phospho-proteomics:Article Title: CDK2 inhibitors and methods of using the same Article Snippet: .. In the assay, Electrophoresis:Article Title: CDK2 inhibitors and methods of using the same Article Snippet: .. In the assay, Incubation:Article Title: Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects. Article Snippet: Cyclin-dependent kinase 9 (CDK9) plays a pivotal role in regulating transcriptional elongation and has emerged as a promising target in cancer therapy.. However, it is reported that CDK9 inhibitors cause abnormal upregulation of H3K27me3 in Diffuse Large B-cell Lymphoma (DLBCL) cell lines.. Here, we designed a series of dual inhibitors targeting CDK9 and EZH2 by linking two distinct pharmacophores to achieve synergistic antitumor effects. |